Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma.
Brown
K S
KS
Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Internal Medicine and Holden Comprehensive Cancer Center, University of Iowa, Iowa City, 52242, USA.
Levitt
D J
DJ
Shannon
M
M
Link
B K
BK
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D008224:Lymphoma, Follicular / Q000276:immunology / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy*; D018579:Patient Selection; D012008:Recurrence
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D006684:HLA-DR Antigens